Immutep Plunges After IDMC Halts Phase III Lung Cancer Study
Immutep Limited said an Independent Data Monitoring Committee recommended stopping its TACTI-004 Phase III trial of eftilagimod alfa in first-line non-small cell lung cancer for futility. The announcement triggered an 80% decline in the company's shares on Friday. Immutep will halt enrollment, conduct an orderly wind down of the study, follow up wi…